Methotrexate (injection)

Revision as of 20:25, 9 August 2011 by Lakshmi Gopalakrishnan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Template:Redirect3

Methotrexate (injection)
Clinical data
Pregnancy
category
  • AU: D
  • US: X (Contraindicated)
Routes of
administration
oral, IV, IM, SC, intrathecal
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability17–90%
Metabolismhepatic
Elimination half-life3–15 hours (dose dependent)
Excretionrenal 48–100%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H22N8O5
Molar mass454.44 g/mol

WikiDoc Resources for Methotrexate (injection)

Articles

Most recent articles on Methotrexate (injection)

Most cited articles on Methotrexate (injection)

Review articles on Methotrexate (injection)

Articles on Methotrexate (injection) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Methotrexate (injection)

Images of Methotrexate (injection)

Photos of Methotrexate (injection)

Podcasts & MP3s on Methotrexate (injection)

Videos on Methotrexate (injection)

Evidence Based Medicine

Cochrane Collaboration on Methotrexate (injection)

Bandolier on Methotrexate (injection)

TRIP on Methotrexate (injection)

Clinical Trials

Ongoing Trials on Methotrexate (injection) at Clinical Trials.gov

Trial results on Methotrexate (injection)

Clinical Trials on Methotrexate (injection) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Methotrexate (injection)

NICE Guidance on Methotrexate (injection)

NHS PRODIGY Guidance

FDA on Methotrexate (injection)

CDC on Methotrexate (injection)

Books

Books on Methotrexate (injection)

News

Methotrexate (injection) in the news

Be alerted to news on Methotrexate (injection)

News trends on Methotrexate (injection)

Commentary

Blogs on Methotrexate (injection)

Definitions

Definitions of Methotrexate (injection)

Patient Resources / Community

Patient resources on Methotrexate (injection)

Discussion groups on Methotrexate (injection)

Patient Handouts on Methotrexate (injection)

Directions to Hospitals Treating Methotrexate (injection)

Risk calculators and risk factors for Methotrexate (injection)

Healthcare Provider Resources

Symptoms of Methotrexate (injection)

Causes & Risk Factors for Methotrexate (injection)

Diagnostic studies for Methotrexate (injection)

Treatment of Methotrexate (injection)

Continuing Medical Education (CME)

CME Programs on Methotrexate (injection)

International

Methotrexate (injection) en Espanol

Methotrexate (injection) en Francais

Business

Methotrexate (injection) in the Marketplace

Patents on Methotrexate (injection)

Experimental / Informatics

List of terms related to Methotrexate (injection)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Methotrexate (rINN) (IPA: Template:IPA), abbreviated MTX and formerly known as amethopterin, is an antimetabolite and antifolate drug used in treatment of cancer and autoimmune diseases. It acts by inhibiting the metabolism of folic acid. Methotrexate replaced the more powerful and toxic antifolate aminopterin, and the two should not be confused with each other.

History

Methotrexate originated in the 1940s when Sidney Farber at Children's Hospital Boston was testing the effects of folic acid on cancer. This inspired chemists at the drug company Lederle to start looking for antimetabolites resembling folate. The result was methotrexate, which was developed in 1948 by Yellapragada Subbarao from Lederle. Methotrexate gained Food and Drug Administration (FDA) approval as an oncology drug in 1953.

Uses

In chemotherapy

Methotrexate was originally used, as part of combination chemotherapy regimens, to treat many kinds of cancers. It is still the mainstay for the treatment of many neoplastic disorders including acute lymphoblastic leukemia.

Other uses

More recently it has come into use as a treatment for some autoimmune diseases, including ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis (see disease-modifying antirheumatic drugs). A parallel use with TNFα blockers as infliximab or etanercept has been shown to markedly improve symptoms.[1]

Although not indicated for this use, methotrexate is also sometimes used (generally in combination with misoprostol) to terminate early pregnancies, particularly ectopic pregnancies.

Pharmacokinetics

Methotrexate is a weak dicarboxylic acid with pKa 4.8 and 5.5, and thus it is mostly ionized at physiologic pH. Oral absorption is saturatable and thus dose-dependent, with doses less than 40mg/M2 having 42% bioavailability and doses greater than 40mg/M2 only 18%. Mean oral bioavailability is 33% (13-76% range), and there is no clear benefit to subdividing an oral dose. Mean intramuscular bioavailability is 76%.

Methotrexate is metabolized by intestinal bacteria to the inactive metabolite 4-amino-4-deoxy-N-methylpteroic acid (DAMPA) and accounts for less than 5% loss of the oral dose.

Factors that decrease absorption include food, oral non-absorbable antibiotics (e.g. vancomycin, neomycin, and bacitracin), and more rapid transit through the Gastrointestinal (GI) tract such as diarrhea, while slower transit time in the GI tract from constipation will increase absorption.

Administration

It can be taken orally or administered by injection (subcutaneous, intramuscular, intravenous or intrathecal). Although daily preparations are occasionally used, most patients take weekly doses, which decreases the risk of certain side-effects.

Adverse effects

Possible side effects can include anemia, neutropenia, increased risk of bruising, nausea and vomiting, dermatitis and diarrhea. A small percentage of patients develop hepatitis, and there is an increased risk of pulmonary fibrosis.

The higher doses of methotrexate often used in cancer chemotherapy can cause toxic effects to the rapidly-dividing cells of bone marrow and gastrointestinal mucosa. The resulting myelosuppression and mucositis are often prevented (termed methotrexate "rescue") by using folinic acid supplements (not to be confused with folic acid).

Methotrexate is a highly teratogenic drug and categorized in Pregnancy Category X by the FDA. Women must not take the drug during pregnancy, if there is a risk of becoming pregnant, or if they are breastfeeding. Men who are trying to get their partner pregnant must also not take the drug. To engage in any of these activities (after discontinuing the drug), women must wait until the end of a full ovulation cycle and men must wait three months.

There is a risk of a severe adverse reaction if penicillin is prescribed alongside methotrexate.

Interestingly, there have also been some reports of central nervous system reactions to methotrexate especially when given via the intrathecal route which include myelopathies and leucoencephalopathies.

Mode of action

Methotrexate competitively and reversibly inhibits dihydrofolate reductase (DHFR), an enzyme that is part of the folate synthesis metabolic pathway. The affinity of methotrexate for DHFR is about one thousand-fold that of folate for DHFR. Dihydrofolate reductase catalyses the conversion of dihydrofolate to the active tetrahydrofolate. Folic acid is needed for the de novo synthesis of the nucleoside thymidine, required for DNA synthesis. Also, folate is needed for purine base synthesis, so all purine synthesis will be inhibited. Methotrexate, therefore, inhibits the synthesis of DNA, RNA, thymidylates, and proteins.

Methotrexate acts specifically during DNA and RNA synthesis, and thus it is cytotoxic during the S-phase of the cell cycle. Logically, it therefore has a greater toxic effect on rapidly dividing cells (such as malignant and myeloid cells, and GI & oral mucosa), which replicate their DNA more frequently, and thus inhibits the growth and proliferation of these non-cancerous cells as well causing side effects listed above.

Lower doses of methotrexate have been shown to be very effective for the management of rheumatoid arthritis and psoriasis. In these cases inhibition of dihydrofolate reductase (DHFR) is not thought to be the main mechanism, rather the inhibition of enzymes involved in purine metabolism, leading to accumulation of adenosine, or the inhibition of T cell activation and suppression of intercellular adhesion molecule expression by T cells.[2]

References

  1. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004). "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial". Lancet. 363 (9410): 675–81. PMID 15001324.
  2. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H; (2005). "The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules". Clin Immunol. 114 (Feb.): 154–163. PMID 15639649.

Template:Immunosuppressants Template:SIB

de:Methotrexat hu:Metotrexát nl:Methotrexaat zh-yue:甲氨喋呤


Template:WikiDoc Sources